Spotlight On... NICE rebuffs Roche's Kadcyla, BMS' Opdivo in latest round of cancer rejections; AstraZeneca's new Tagrisso wins short reprieve from Clovis rival; Merck nabs expanded Gardasil 9 approval in males; and more...

Cost-effectiveness watchdogs in the U.K. dealt another couple of blows to pricey cancer drugs. The National Institute for Health and Care Excellence gave a final thumbs-down to Roche's ($RHHBY) breast cancer med Kadcyla, despite the drugmaker's discount offer. Agency reviewers also recommended against using Bristol-Myers Squibb's ($BMY) Opdivo in squamous non-small cell lung cancer, saying the immunotherapy was too costly for its admittedly notable clinical benefits. More from FiercePharma

> Clovis Oncology ($CLVS) said the FDA is extending its review of a new lung cancer treatment, rociletinib, giving AstraZeneca ($AZN) more time to build momentum for its rival med Tagrisso, approved last month. Report

> Merck & Co. ($MRK) won an expanded indication for its HPV vaccine Gardasil 9 in boys and young men aged 16 to 26. Release

> Kantar Health bought the Prague-based market research, analytics and consulting firm CEEOR to beef up its suite of services for clients in Europe. Release

> Specialty drug costs blew a $438 million hole in the California Public Employees' Retirement System budget, a 32% increase year-over-year; the amount represented one-fourth of its drug spending, dollarwise, though specialty drugs accounted for only 1% of prescriptions. Report

And Finally... Johnson & Johnson's ($JNJ) atypical antipsychotic Risperdal appears to trigger a well-known side effect--weight gain--by interfering with gut microbes, a new study suggests. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.